Anti-alpha V immunoliposome compositions, methods and uses

US8138315B2 · kind B2 · utility

Assignee

• Centocor Ortho Biotech Inc. · US

Inventors

• Joshua Goldstein · Radnor, US
• Allen Magill · Radnor, US
• Deepak Saini · Radnor, US
• Linda Snyder · Pottstown, US
• Raymond Sweet · Via Enrico Fermi, US
• Steve P. Weng · Fremont, US

Key dates

• Filing date: May 11, 2011
• Grant date: Mar 20, 2012
• Expiry date: May 11, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/622
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

An immunoliposome composition targeted to the alphaV-integrin subunit of integrin receptors comprised of ligand-targeted liposomes bearing at least one targeting-ligand derived from an antibody and having binding specificity for at least one integrin receptor comprising an alpha V subunit including αvβ1, αvβ3 αvβ5, αvβ6, or αvβ8 integrin cell receptors is described. The antibody-derived targeting ligand may be a Fab′ fragment, a scFv, or the like. Binding of the immunoliposome to αv-integrin expressing cells, preferably results in internalization of the immunoliposome for cytoplasmic delivery of a liposome-entrapped agent.